Difference between revisions of "Interferon gamma-1a (Imunomax-γ)"
Jump to navigation
Jump to search
(Created page with "==General information== Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways. ==D...") |
m |
||
| (One intermediate revision by one other user not shown) | |||
| Line 4: | Line 4: | ||
*[[Cutaneous T-cell lymphoma]] | *[[Cutaneous T-cell lymphoma]] | ||
==History of changes in PMDA indication== | ==History of changes in PMDA indication== | ||
| − | *2014-05-23: | + | *2014-05-23: New additional indications and a new dosage for the treatment of [[Cutaneous T-cell lymphoma|mycosis fungoides and Sézary syndrome]]. |
==Also known as== | ==Also known as== | ||
*'''Brand name:''' Imunomax-γ | *'''Brand name:''' Imunomax-γ | ||
| Line 12: | Line 12: | ||
[[Category:Drugs]] | [[Category:Drugs]] | ||
[[Category:Cutaneous T-cell lymphoma medications]] | [[Category:Cutaneous T-cell lymphoma medications]] | ||
| − | [[Category: | + | [[Category:Interferon gammas]] |
[[Category:Stub]] | [[Category:Stub]] | ||
Latest revision as of 14:12, 1 August 2023
General information
Class/mechanism: Immune system activator; binds to cell surface receptors that modulate many downstream intracellular signal transduction pathways.
Diseases for which it is used
History of changes in PMDA indication
- 2014-05-23: New additional indications and a new dosage for the treatment of mycosis fungoides and Sézary syndrome.
Also known as
- Brand name: Imunomax-γ